Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

Related Keywords

Epalinges ,Switzerland General ,Switzerland ,France ,Paris ,France General ,Taipei ,T Ai Pei ,Taiwan ,Alain Herrera ,Biomunex Pharmaceuticals ,Onward Therapeutics ,Chief Medical ,Bispecific Antibody ,Hematological Malignancies ,Phase 1 Clinical Trial ,Herapeutics ,Development ,Immune Checkpoints ,Iopharmaceutical Company ,Drug Development ,Solid Tumors ,Cancer Treatment ,